Citius Pharmaceuticals
Update in progressCTXR (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Citius Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing critical care products. Its FDA-approved product, LYMPHIR, is a targeted immunotherapy for cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical for hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for ARDS. Founded in 2007 and based in Cranford, NJ.
Company score
- Sentiment
- 0.51
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.46
- Governance
- 0.13
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.16
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.33
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Leonard L. Mazur
- Founded2007
- Employees23
- Websitecitiuspharma.com
Identifiers
- ISINUS17322U2078
- FIGIBBG001QQH2N3
- LEI5493005C10W36P4KQP40
- CUSIP17322U207
- CIK0001506251